Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 20:15:3475-3486.
doi: 10.2147/NDT.S218578. eCollection 2019.

Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia

Cristina Domenech  1   2 , Adriana Pastore  3 , A Carlo Altamura  4 , Corrado Bernasconi  5 , Ricardo Corral  6 , Helio Elkis  7 , Jonathan Evans  8 , Ashok Malla  9 , Francesco Margari  3 , Marie-Odile Krebs  10 , Anna-Lena Nordstroem  5 , Mathias Zink  11 , Josep Maria Haro  1   2
Affiliations

Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia

Cristina Domenech et al. Neuropsychiatr Dis Treat. .

Abstract

Background: Generic health-related quality of life (HRQoL) scales are increasingly being used to assess the effects of new treatments in schizophrenia. The objective of this study is to better understand the usefulness of generic and condition specific HRQoL scales in schizophrenia by analyzing their correlates.

Methods: Data formed part of the Pattern study, an international observational study among 1379 outpatients with schizophrenia. Patients were evaluated with the Mini International Neuropsychiatric Inventory, the Clinical Global Impression-Schizophrenia (CGI-SCH) Scale and the Positive and Negative Syndrome Scale (PANSS) and reported their HRQoL using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D). The two summary values of the SF-36 (the Mental Component Score and the Physical Component Score, SF-36 MCS and SF-36 PCS) were calculated.

Results: Higher PANSS positive dimension ratings were associated with worse HRQoL for the SQLS, EQ-5D VAS, SF-36 MCS, and SF-36 PCS. Higher PANSS negative dimension ratings were associated with worse HRQoL for the EQ-5D VAS, SF-36 MCS, and SF-36 PCS, but not for the SQLS or the EQ-5D tariff. PANSS depression ratings were associated with lower HRQoL in all the scales. There was a high correlation between the HRQoL scales. However, in patients with more severe cognitive/disorganized PANSS symptoms, the SQLS score was relatively higher than the EQ-5D tariff and SF-36 PCS scores.

Conclusion: This study has shown substantial agreement between three HRQoL scales, being either generic or condition specific. This supports the use of generic HRQoL measures in schizophrenia.

Clinicaltrialsgov identifier: NCT01634542 (July 6, 2012, retrospectively registered).

Keywords: epidemiology; health-related quality of life; persistent symptoms; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Carlo Altamura has served as a consultant or advisory board member for F. Hoffmann- La Roche, Ltd., Lundbeck, Merck, Astra Zeneca, Bristol Myers Squibb, Janssen-Cilag, Sanofi, Eli Lilly, Pfizer and Otsuka. Corrado Bernasconi is a contractor of F. Hoffmann- La Roche, Ltd. Helio Elkis has received research grants from the São Paulo Research Foundation (FAPESP), Janssen-Cilag and Roche, participated on advisory boards for Janssen-Cilag and Roche, and received honoraria and travel support from Janssen-Cilag and Roche. Ashok Malla has received honoraria or participated in advisory boards or educational conferences or received research funding for investigator-initiated projects from Janssen Canada, Pfizer Canada, Bristol-Myers-Squib, F. Hoffmann- La Roche, Ltd., Otsuka, Lundbeck and Astra-Zeneca. Francesco Margari has no conflict of interest. Anna-Lena Nordstroem is an employees of F. Hoffmann- La Roche, Ltd. Mathias Zink has received unrestricted scientific grants from the European Research Advisory Board, German Research Foundation, Servier, Pfizer Pharma GmbH, Bristol-Myers Squibb GmbH & CoKGaA, further speaker and travel support from Pfizer Pharma GmbH, Bristol-Myers Squibb, Otsuka, Astra Zeneca, Eli-Lilly, Janssen Cilag, Servier, Trommsdorff and F. Hoffmann- La Roche Ltd. Marie-Odile Krebs has received honoraria and participated in advisory boards F. Hoffmann- La Roche, Ltd. Josep Maria Haro has acted as a consultant, participated in advisory boards or given educational presentations for Eli Lilly and Co., Lundbeck, Otsuka, F. Hoffmann- La Roche Ltd. and Takeda. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Scatter plot figures of the relationship among the quality of life scales. ***p<0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Millier A, Clay E, Charaf I, et al. Patient reported outcomes instruments in schizophrenia : a review of psychometric properties. Open J Med Psychol. 2014;2014(1):141–156. doi:10.4236/ojmp.2014.32017 - DOI
    1. Awada G, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6(1):21–26. doi:10.1023/a:1026409326690 - DOI - PubMed
    1. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. 2012;30(3):183–195. doi:10.2165/11594470 - DOI - PubMed
    1. Seow LSE, Tan THG, Abdin E, Chong SA, Subramaniam M. Comparing disease-specific and generic quality of life measures in patients with schizophrenia. Psychiatry Res. 2019;273(January):387–393. doi:10.1016/j.psychres.2019.01.034 - DOI - PubMed
    1. Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in Schizophrenia? A systematic review. Value Heal. 2011;14(6):907–920. doi:10.1016/j.jval.2011.04.006 - DOI - PMC - PubMed

Associated data